@article{3d7634d8188f436da68bd68edf7c51df,
title = "Class I HLA-A*7401 is associated with protection from HIV-1 acquisition and disease progression in Mbeya, Tanzania",
abstract = "Here we explore associations between HLA variation and human immunodeficiency virus type 1 (HIV-1) acquisition and disease progression in a community cohort in Mbeya, Tanzania, a region that, despite harboring high rates of HIV-1 infection, remains understudied. African-specific allele HLA-A*74:01 was associated with decreased risk of infection (odds ratio [OR], 0.37; 95\% confidence interval [CI], 0.14-0.80; P = .011) and with protection from CD4+ cell counts <200 cells/uL in women (OR, 0.31; 95\% CI, 0.07-0.91; P = .032) and men (OR, 0.15; 95\% CI, 0.01-0.78; P = .020). These associations remained significant after adjustment for linkage disequilibrium with HLA-B and HLA-C alleles. This observation calls for additional investigation of mechanisms by which HLA-A*74:01 may influence HIV-1 acquisition and control of the infection.",
author = "Koehler, \{Rebecca N.\} and Walsh, \{Anne M.\} and Elmar Saathoff and Sodsai Tovanabutra and Arroyo, \{Miguel A.\} and Currier, \{Jeffery R.\} and Leonard Maboko and Michael Hoelsher and Robb, \{Merlin L.\} and Michael, \{Nelson L.\} and McCutchan, \{Francine E.\} and Kim, \{Jerome H.\} and Kijak, \{Gustavo H.\}",
note = "Funding Information: HLA allele and carrier frequencies were determined by direct counting. Haplotype frequencies were computed using PyPop software, distributed by the authors (version 0.6.0; http://www .pypop.org). Odds ratios were determined using logistic regression (JMP software, version 7.0.02; SAS Institute). Time-to-event analysis was determined using Kaplan-Meier life-table methods with significance assessed using the log-rank tests. The study was conducted jointly by the Mbeya Regional AIDS Control Programme (Tanzanian Ministry of Health), the Department of Infectious Diseases and Tropical Medicine, Ludwigs-Maximillians University (Munich, Germany), and the US Military HIV Research Program (MHRP, Rockville, Maryland). Review boards of participating institutions approved the study protocols, and informed consent was obtained from all study participants. Funding Information: Financial support: This work was supported through a cooperative agreement between the Henry M. Jackson Foundation for the Advancement of Military Medicine and the US Department of Defense, by the National Institute for Allergy and Infectious Diseases (NIAID), and National Institutes of Health (NIH) (grant Y01 AI2642-12). Funding Information: The US Military HIV Research Program is jointly planned and funded by the DOD and NIAID/NIH by an interagency agreement. This manuscript was approved for publication by the Walter Reed Army Institute of Research. The views and opinions expressed herein are those of the authors and do not necessarily reflect those of the US Army or the Department of Defense or the National Institutes of Health.",
year = "2010",
month = nov,
day = "15",
doi = "10.1086/656913",
language = "English",
volume = "202",
pages = "1562--1566",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "10",
}